Episode Details

CVS Health Corporation (CVS) Q2 2026 — Revenue $106,096M, UP 7.3% YoY, about $5.0B ahead of the bar. Adjusted operating income $5,157M, UP 35.4%. Adjusted EPS $2.58 vs a $1.87 consensus - a 38% beat, adjusted against adjusted. GAAP EPS $2.31 vs $0.80. Aetna MBR 87.4% vs 89.9%. FY26 adjusted guide RAISED to $7.90-$8.10 from $7.30-$7.50. Stock opened DOWN 10.4% and closed the day near $99.90, off 4.3%. CVS beat the adjusted consensus by 38% and raised full-year guidance for the second time this year - and the stock opened down 10.4%. The reason is one subtraction: the beat was $0.71, the raise was $0.60, so the implied second half was trimmed by eleven cents. Then management put a preliminary 2027 floor of $8.44 on the call, exactly where consensus already sat. THE CALL: HOLD (3/5, THE TURNAROUND IS REAL, IT IS FINISHED, AND IT IS ALREADY IN THE PRICE) — base-case value ~$100.28 vs ~$99.9 today. KEY METRICS: - CALL: HOLD 3/5, fair value ~$100 vs $99.90 (level), BELOW the Street's $108.86 average (+9%). Base case: 2028 adjusted EPS of $9.30 on a 12.5x exit multiple discounted at 9% plus dividends = $100.28. Bear $67.55 (Aetna's recovery stalls, Caremark leaks members, 10x on $7.60). Bull $121.87 (full return to peak earnings power, $10.20 on 14x). Run backwards, $99.90 already requires 2028 adjusted EPS of $9.26 - 7.6% a year. Management's own preliminary 2027 floor is 5.5%. The Street's $108.86 needs 12.6%. - THE RAISE WAS SMALLER THAN THE BEAT, AND THAT IS THE WHOLE STORY. CVS beat by $0.71 ($2.58 vs $1.87) and raised the FY adjusted guide by $0.60 at the midpoint ($7.30-$7.50 to $7.90-$8.10). So the implied second half was CUT by $0.11. Three independent checks: H1 adjusted EPS was $5.16, so the implied H2 is $2.84 - 55% of H1, against 66% last year ($4.06 then $2.69). And $2.84 vs last year's $2.69 is +5.6% growth, after a first half that grew 27%. - THE BEAT IS NOT A RESERVE GAME - WE CHECKED, AND IT IS CLEANER THAN LAST YEAR. Favourable development on prior years' claims was $1.2B in H1 2026 against $1.9B in H1 2025 - $700M LESS release. Premium deficiency reserves went from $902M to $15M. Days claims payable were 41.7 at June 30 against 40.9 a year ago - UP. The one genuine flatterer is the absence of last year's $471M Group Medicare Advantage deficiency reserve: strip it and Aetna's adjusted operating income still grew 36.4%, not 85.5%. - ONE SEGMENT DID 83% OF THE WORK. Of the $1,349M of additional adjusted operating income, $1,118M came from Aetna alone, on an MBR that fell from 89.9% to 87.4% with membership flat at 26.0M. Caremark added $158M on $5,342M of extra revenue - a 3.0% incremental margin, with claims flat at 473.0M and its operating margin slipping from 3.4% to 3.3%. Retail added $137M on revenue up 0.7%. Management has guided Caremark MEMBERSHIP DECLINES for 2027, plus 340B headwinds. - THE CASH IS REAL AND THE GUIDANCE IS SANDBAGGED. First-half operating cash flow was $10,594M against $6,453M a year ago, up 64%, on $1,540M of capex. Full-year guidance is 'at least $11.5B' - but H1 alone was $10.6B, implying under $1B in the back half. Total debt is $61,410M ($59,452M long-term plus $1,958M current) against $11,329M of cash - $50,081M net, 39% of the market cap. In the half: $1,725M of dividends, $3,287M of debt repaid, and zero buyback. What to watch: Changes our mind UP: a Q3 that beats the implied $2.84 second half, an MBR holding below 88% through December, or the start of a share repurchase. Confirms the bear: Caremark membership losses larger than guided, days claims payable back below 40, or PBM legislation with teeth. We would buy $80-$88. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.